Sign InCreate an Account
Sign InCreate an Account

This website is for HealthCare Professional audiences in the U.K. Adverse event information can be found at the bottom of this page.

Discover
Nuceiva®

(Botulinum Toxin Type A)

NUCEIVA is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.1

Neuromodulator
Treatment

Acts in 2 days6
At day 2, the percentages of responders in each of the Nuceiva®, Botox® and placebo groups were 54.2%, 57.0%, and 12.2%, respectively. The test of superiority of Nuceiva® vs placebo was highly statistically significant: the absolute difference in the percentages of responders was 41.9% (P < 0.001).

Lasts up to 4 months 1
Nuceiva® injections significantly reduced the severity of glabellar lines by 1 point or greater at maximum frown for up to 139 days, as measured by the investigator assessment of glabellar line severity at maximum frown.

High patient satisfaction 91.3%6
Proportion of patients with at least a 1-point improvement on the subject satisfaction scale (SSS) at day 30 (ie, a score of 1 [satisfied] or 2 [very satisfied]). The percentages of responders in each of the Nuceiva®, Botox® and placebo groups were 91.3%, 86.6%, and 6.3%, respectively. The test of superiority of Nuceiva® vs placebo was highly statistically significant: the absolute difference in the percentages of responders was 85.0% (P < 0.001).

Inside the Nuceiva vial

  • Botulinum toxin type A1
  • Human serum albumin1
  • Sodium chloride (NaCl)1
  • Finishing method: vacuum dried6 Stored at 2-7C1
Sign up to learn more

Nuceiva administration

  • Injected intramuscularly into 5 sites1
  • 2 in each corrugator (inferior medial & superior medial)1
  • 1 in the procerus muscle1
See Nuceiva injected - Enrol in our course

References

1. Nuceiva SmPC

2. FDA. Jeuveau Drugs@FDA: FDA Approved Drug Products. Last Reviewed 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (Accessed: 11/2023)

  1. European Commission. Granting Marketing Authorisation of Nuceiva in the European Union. 27 September 2019

  2. HRES Gov Canada. Product Monograph Nuceiva. Last reviewed 2018. https://pdf.hres.ca/dpd_pm/00046932.PDF (Accessed: 11/2023)

  3. Australian Government Therapeutic Goods Administration. Nuceiva Approval Letter. 13 January 2023

  4. Rzany, Berthold-Josef, et al. 2021 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients. Aesthetic Surgery Journal. 2019 doi.org/10.1093/asj/sjz110 

ADVERSE EVENTS SHOULD BE REPORTED.

Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.

Adverse events should also be reported to Evolus International Ltd.

Please contact Evolus Europe Medical Information by medicalinformation@evolus.com or calling 08000541302.

Report an Adverse EventPrescribing Information